StocksMediumUpdated•Originally published 26 March 2026•Updated 27 March 2026•
1 min read
Wave Life Sciences Shares Plunge 50% Despite Positive Obesity Drug Trial Data
Key Facts
1Wave Life Sciences (WVE) shares plummeted 50% in a single trading day despite management describing obesity drug trial results as 'positive'.
2Phase 1 data for WVE-007 showed a 14% loss in visceral fat at a 240 mg dose, but the stock broke below its 200-day moving average.
3Oppenheimer analyst Cheng Li called the drop a 'generational' investment opportunity despite the stock being down 60% year-to-date.
Wave Life Sciences (WVE) shares collapsed by 50% in a single session following the release of data from the INLIGHT Phase 1 clinical trial for its obesity treatment, WVE-007. While the data showed a 14% reduction in visceral fat at a 240 mg dosage, two Wall Street firms responded by cutting their price targets for the company. The market's negative reaction pushed the stock below its 200-day moving average, triggering significant algorithmic selling pressure. Despite the plunge, Oppenheimer analyst Cheng Li characterized the decline as a 'generational' investment opportunity, noting the stock's 60% year-to-date drop. The event underscores the intense competition in the obesity drug market and the inherent volatility of the biotech sector.